What it sells
Robotic production capacity for the pharma manufacturing industry
Business model breakdown
Buyer: who owns the budget?
UnverifiedVP manufacturing / CMC at advanced-therapy developers and CDMOs.
Trigger: what makes them buy now?
Demand for advanced therapies outpaces manual cleanroom manufacturing; cost per dose, contamination risk and traceability.
Workflow: what inputs become what output?
Customer's existing GMP instruments are placed in a robotic cluster (4 UR arms, up to 24 instrument modules); scientists build the process in a no-code Process Creator App and robots execute it in a closed cleanroom.
Economics: what it saves and how it charges
Site claims 74% cost reduction per dose, 90% of cleanroom steps automated, 100x throughput per sq ft, 2,000-10,000+ doses/year per cluster; sold as robotic systems (price not shown).
Distribution: how it reaches customers
Direct enterprise sales and collaborations ('Request an In-Person Visit').
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2016 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.